Anti-PD-L1 and SAbR for Ovarian Cancer

NCT03312114 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

5

Enrollment

OTHER

Sponsor class

Stopped low accrual

Conditions

Recurrent Epithelial Cancer of Ovary
Primary Peritoneal Carcinoma
Fallopian Tube Cancer

Interventions

DRUG: Avelumab

Sponsor

University of Texas Southwestern Medical Center

Collaborators

[object Object]